The future of drug pricing and reimbursement was the topic of a presentation by Henry Dummett, managing editor for health care at the Economist Intelligence Unit, to the recent 14th annual Pharmaceuticals Conference, hosted by The Economist in London, UK (Marketletters passim). He examined the likely pressures which are expected to impact pricing systems by 2020.
The conference also heard from Arthur Higgins, president of the European Federation of Pharmaceutical Industries and Associations as well as chief executive of Germany's Bayer HealthCare, who said that current health care systems are not sustainable in the long-term due to the double burden of an aging population and the growing cost of managing lifestyle-related diseases. Mr Higgins' vision of industry/patient relations in the future also included the observations that there is a "crisis in R&D," which is caused by soaring costs in the area, more complex regulation and a negative shift in risk-benefit assessments. The EFPIA president forecast "a train wreck for health care in Europe, 10-20 years from now," (Marketletter March 3). In this context, pressure on payers to achieve greater value for money is to be expected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze